A look at the top drug delivery stocks; Nanotech may be the future, but what are its risks?;

 @DamianFierce: The coming onslaught of blockbuster knockoffs could be a huge opportunity for drug delivery firms. News | Follow @DamianFierce

> Valeant Pharmaceuticals ($VRX) leads a list of the highest-performing drug delivery stocks, compiled by Benzinga. Report

> Medical News Today takes a closer look at the rise of nanotechnological treatments and their possible risk factors. Story

> Apricus Biosciences ($APRI) is heading toward commercialization in Canada for Femprox, which uses its patented transdermal delivery cream. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.